The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.00
Bid: 1,798.00
Ask: 1,799.00
Change: 10.50 (0.59%)
Spread: 1.00 (0.056%)
Open: 1,796.00
High: 1,808.50
Low: 1,793.50
Prev. Close: 1,788.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK publishes Annual Report 2023

1 Mar 2024 12:15

RNS Number : 2981F
GSK PLC
01 March 2024
 

 

GSK plc

(the 'Company')

 

Publication of Annual Report 2023

 

 

The Company has today published on its website www.annualreport.gsk.com its Annual Report for the year ended 31 December 2023 ('Annual Report 2023').

 

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2023 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

A hard copy version of the Annual Report 2023 and the Notice of Annual General Meeting 2024 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 25 March 2024. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

 

This announcement is not a substitute for reading the Annual Report 2023 in full.

 

Additional Information

 

For the purposes of complying with the FCA's Disclosure and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2023. The Annual Report 2023 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

 

This announcement is made in accordance with DTR 6.3.5R(1A).

 

V A Whyte

Company Secretary

 

1 March 2024

 

?

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEAADFEFALEFA
Date   Source Headline
15th Jan 20214:00 pmRNSDirector/PDMR Shareholding
15th Jan 20213:14 pmRNSDirector/PDMR Shareholding
13th Jan 20211:45 pmRNSDirector/PDMR Shareholding
11th Jan 202111:05 amRNSDirector/PDMR Shareholding
11th Jan 20219:16 amRNSDirector/PDMR Shareholding
4th Jan 202111:25 amRNSTotal Voting Rights
30th Dec 202011:52 amRNSDirector/PDMR Shareholding
23rd Dec 20202:44 pmRNSDirector/PDMR Shareholding
21st Dec 20207:00 amRNSViiV first long-acting HIV regimen approved in EU
11th Dec 20207:00 amRNSSanofi/ GSK update on COVID vaccine candidate
10th Dec 20205:51 pmRNSDirector/PDMR Shareholding
10th Dec 202011:55 amRNSBlock Listing Application
9th Dec 20203:04 pmRNSDirector/PDMR Shareholding
3rd Dec 20205:53 pmRNSDirector/PDMR Shareholding
1st Dec 20203:00 pmRNSTotal Voting Rights
27th Nov 20202:58 pmRNSGSK publishes provisional 2021 dividend dates
26th Nov 202012:35 pmRNSEMTN Supplementary Prospectus
25th Nov 202010:26 amRNSDirector/PDMR Shareholding
23rd Nov 20208:59 amRNSBlock listing Interim Review
19th Nov 20205:40 pmRNSHolding(s) in Company
17th Nov 20205:48 pmRNSDirector/PDMR Shareholding
12th Nov 20201:00 pmRNSMedicago GSK phase 2/3 study start
11th Nov 20203:08 pmRNSDirector/PDMR Shareholding
11th Nov 202011:13 amRNSDirector/PDMR Shareholding
9th Nov 20207:00 amRNSViiV’s cabotegravir superior for HIV prevention
4th Nov 20205:32 pmRNSDirector/PDMR Shareholding
4th Nov 20204:45 pmRNSDirector/PDMR Shareholding
3rd Nov 20204:09 pmRNSDirector/PDMR Shareholding
3rd Nov 20208:00 amRNSGSK sets new environmental goals
2nd Nov 20205:16 pmRNSDirector/PDMR Shareholding
2nd Nov 20203:59 pmRNSTotal Voting Rights
30th Oct 20205:08 pmRNSHolding(s) in Company
30th Oct 202012:53 pmRNSDirector/PDMR Shareholding
28th Oct 20205:46 pmRNSDirector/PDMR Shareholding
28th Oct 202012:00 pmRNS3rd Quarter Results
28th Oct 20207:00 amRNSSanofi and GSK support COVAX - 200m vaccine doses
22nd Oct 202012:34 pmRNSHolding(s) in Company
16th Oct 202012:18 pmRNSPositive CHMP opinion ViiV long-acting HIV regimen
14th Oct 20203:30 pmRNSDirector/PDMR Shareholding
14th Oct 20203:29 pmRNSDirector/PDMR Shareholding
13th Oct 20202:41 pmRNSDirector/PDMR Shareholding
13th Oct 20202:08 pmRNSDirector/PDMR Shareholding
13th Oct 20202:01 pmRNSDirector/PDMR Shareholding
13th Oct 20201:55 pmRNSDirector/PDMR Shareholding
13th Oct 20201:49 pmRNSDirector/PDMR Shareholding
1st Oct 20204:30 pmRNSTotal Voting Rights
22nd Sep 20205:42 pmRNSSanofi/GSK agree up to 72m Canada COVID doses
11th Sep 20203:17 pmRNSDirector/PDMR Shareholding
10th Sep 202010:01 amRNSDirector/PDMR Shareholding
9th Sep 20203:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.